All In Biotech

Drug Trial Radar · NCT05376150

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

May 19, 2022

Primary completion

Sep 18, 2023

Study completion Oct 16, 2023

Sponsor

Lead sponsor
Xenon Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
May 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

Conditions

  • Major Depressive Disorder

Interventions

  • XEN1101 10 mgDrug

    XEN1101 oral capsule

  • XEN1101 20 mgDrug

    XEN1101 oral capsule

  • PlaceboDrug

    Placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.Time frame: From baseline to end of treatment (Week 6).

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Research Center

    Anaheim, California

  • Sunwise Clinical Research, LLC

    Lafayette, California

  • California Neuropsychopharmacology Clinical Research Institute

    Pico Rivera, California

  • Artemis Institute for Clinical Research

    Riverside, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Meridian International Research

    Miami, Florida

  • Global Medical Institutes (GMI)

    Miami, Florida

  • CCM Clinical Reseach Group, LLC

    Miami, Florida

  • i-Research, Atlanta

    Decatur, Georgia

  • Psych Atlanta, PC

    Marietta, Georgia

  • iResearch

    Savannah, Georgia

  • Revive Research Institute, Inc.

    Elgin, Illinois

  • Altea Research

    Las Vegas, Nevada

  • Hassman Research Institute

    Marlton, New Jersey

  • Bio Behavioral Health

    Toms River, New Jersey

  • Neurobehavioral Research, Inc. (NBR)

    Cedarhurst, New York

  • Manhattan Behavioral Medicine, PLLC

    New York, New York

  • Richard M Weisler and Association

    Raleigh, North Carolina

  • FutureSearch Trials of Dallas, LP

    Dallas, Texas

  • AIM Trials

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.